The PD-1 inhibitor and JX-594 combination (mean primary tumor weight = 0.71 g) and ICI combination (mean primary tumor weight = 0.98 g) had significantly different effects on the primary tumor burden in the early-stage (P < 0.05) (Fig. 2A). This evidence concerns the gene PDCD1 and neoplasm.